Hyldahl Emil, Gotfredsen Klaus, Lynge Pedersen Anne Marie, Storgård Jensen Simon
Oral Surgery, Section for Oral Biology and Immunopathology, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, CopenhagenDenmark.
Oral Rehabilitation, Section for Oral Health, Society and Technology, Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, CopenhagenDenmark.
J Oral Maxillofac Res. 2024 Mar 31;15(1):e1. doi: 10.5037/jomr.2024.15101. eCollection 2024 Jan-Mar.
The purpose of this systematic review is to disclose the impact of autoimmune diseases and their medical treatment on dental implant survival and success.
A literature search was conducted using MEDLINE (PubMed), The Cochrane Library and Embase up to December 6, 2021. Any clinical study on patients with an autoimmune disease in whom implant therapy was performed was eligible. The quality of included studies was assessed using the Newcastle-Ottawa Scale. For each autoimmune disease group, data synthesis was divided into three groups: 1) overall results of the autoimmune disease, 2) overall results of corresponding control groups and 3) overall results of the autoimmune disease with a concomitant autoimmune disease (a subgroup of group 1). Descriptive statistics were used.
Of 4,865 identified articles, 67 could be included and mainly comprising case reports and retrospective studies with an overall low quality. Implant survival rate was 50 to 100% on patient and implant level after a weighted mean follow-up of 17.7 to 68.1 months. Implant success was sporadically reported. Data on immunosuppressive medication were too heterogeneously reported to allow detailed analysis.
Overall, a high implant survival rate was reported in patients with autoimmune diseases. However, the identified studies were characterized by a low quality. No conclusions could be made regarding implant success and the effect of immunosuppressants due to heterogeneous reporting.
本系统评价旨在揭示自身免疫性疾病及其药物治疗对牙种植体存留率和成功率的影响。
截至2021年12月6日，使用MEDLINE（PubMed）、Cochrane图书馆和Embase进行文献检索。任何对接受种植治疗的自身免疫性疾病患者进行的临床研究均符合纳入标准。采用纽卡斯尔-渥太华量表评估纳入研究的质量。对于每个自身免疫性疾病组，数据综合分为三组：1）自身免疫性疾病的总体结果，2）相应对照组的总体结果，3）合并另一种自身免疫性疾病的自身免疫性疾病的总体结果（第1组的一个亚组）。采用描述性统计方法。
在检索到的4865篇文章中，67篇可被纳入，主要包括病例报告和回顾性研究，总体质量较低。在加权平均随访17.7至68.1个月后，患者和种植体水平的种植体存留率为50%至100%。种植体成功率的报道较为零散。关于免疫抑制药物的数据报告过于分散，无法进行详细分析。
总体而言，自身免疫性疾病患者的种植体存留率较高。然而，纳入的研究质量较低。由于报告内容不一致，无法就种植体成功率和免疫抑制剂的效果得出结论。
